알파GPC
Alpha-GPC
📚 관련 논문 (8편)
1. Lipids Health Dis. 2023 Jun 20;22(1):75. doi: 10.1186/s12944-023-01844-w. Effects of egg yolk choline intake on cognitive functions and plasma choline levels in healthy middle-aged and older Japanese: a randomized double-blinded placebo-controlled parallel-group study. Yamashita S(1), Kawada
2. Neurochem Res. 1996 May;21(5):547-52. doi: 10.1007/BF02527751. Evidence for an in vivo and in vitro modulation of endogenous cortical GABA release by alpha-glycerylphosphorylcholine. Ferraro L(1), Tanganelli S, Marani L, Bianchi C, Beani L, Siniscalchi A. Author information: (1)Institute of P
3. Life Sci. 1993;53(24):1821-32. doi: 10.1016/0024-3205(93)90490-t. Cognition stimulating drugs modulate protein kinase C activity in cerebral cortex and hippocampus of adult rats. Lucchi L(1), Pascale A, Battaini F, Govoni S, Trabucchi M. Author information: (1)Inst. Pharmacological Sciences,
4. J Alzheimers Dis. 2023;92(1):59-70. doi: 10.3233/JAD-221189. Activity of Choline Alphoscerate on Adult-Onset Cognitive Dysfunctions: A Systematic Review and Meta-Analysis. Sagaro GG(1), Traini E(1), Amenta F(1). Author information: (1)Clinical Research, Telemedicine and Telepharmacy Center, S
1. J Clin Med. 2023 Apr 14;12(8):2875. doi: 10.3390/jcm12082875. Choline-Containing Phospholipids in Stroke Treatment: A Systematic Review and Meta-Analysis. Sagaro GG(1), Amenta F(1). Author information: (1)Clinical Research, Telemedicine and Telepharmacy Center, School of Medicinal and Health Products Sciences, University of Camerino, 62032 Camerino, Italy. BACKGROUND: Globally, stroke is the second leading cause of death and disability. In different studies conducted previously, the choline-containing phospholipids citicoline and choline alphoscerate have been proposed as adjuvants in the treatment of acute strokes. A systematic review was conducted to provide updated information on the effects of citicoline and choline alphoscerate in patients with acute and hemorrhagic strokes. METHODS: PubMed/Medline, Scopus, and Web of Science were searched to identify relevant materials. Data were pooled, and odds ratios (OR) were reported for binary outcomes. Using mean differences (MD), we evaluated continuous outcomes. RESULTS: A total of 1460 studies were reviewed; 15 studies with 8357 subjects met the eligibility criteria and were included in the analysis. In our study, citicoline treatment did not result in improved neurological function (NIHSS < 1, OR = 1.05; 95% confidence interval (CI): 0.87-1.27) or functional recovery (mRS < 1, OR = 1.36; 95% CI: 0.99-1.87) in patients with acute stroke. Choline alphoscerate improved neurological function and functional recovery in stroke patients based on the Mathew's scale and the Mini-Mental State Examination (MMSE). CONCLUSION: Citicoline did not improve the neurological or functional outcomes in acute stroke patients. In contrast, choline alphoscerate improved neurological function and functional recovery and reduced dependency in stroke patients. DOI: 10.3390/jcm12082875 PMCID: PMC10143951 PMID: 37109211 Conflict of interest statement: The authors declare no conflict of interest in this work.
2. Drugs Aging. 1993 Mar-Apr;3(2):159-64. doi: 10.2165/00002512-199303020-00006. Multicentre study of l-alpha-glyceryl-phosphorylcholine vs ST200 among patients with probable senile dementia of Alzheimer's type. Parnetti L(1), Abate G, Bartorelli L, Cucinotta D, Cuzzupoli M, Maggioni M, Villardita C, Senin U. Author information: (1)Institute of Gerontology and Geriatrics, University of Perugia, Italy. A multicentre, randomised, controlled study compared the efficacy of l-alpha-glyceryl-phosphorylcholine (alpha GPC) and ST200 (acetyl-l-carnitine) among 126 patients with probable senile dementia of Alzheimer's type (SDAT) of mild to moderate degree. Efficacy was evaluated by means of behavioural scales and psychometric tests. The results showed significant improvements in most neuropsychological parameters in the alpha GPC recipients. Improvements also occurred in the ST200 recipients but to a lesser extent. Tolerability was good in both groups. These positive findings require replication in larger, double-blind, longitudinal studies coupling clinical and biological determinations. DOI: 10.2165/00002512-199303020-00006 PMID: 8477148 [Indexed for MEDLINE]
3. Int J Clin Pharmacol Ther Toxicol. 1992 Sep;30(9):331-5. A comparative study of free plasma choline levels following intramuscular administration of L-alpha-glycerylphosphorylcholine and citicoline in normal volunteers. Gatti G(1), Barzaghi N, Acuto G, Abbiati G, Fossati T, Perucca E. Author information: (1)Department of Internal Medicine and Therapeutics, University of Pavia, Italy. L-alpha-glycerylphosphorylcholine (alpha-GPC) is a recently developed cognitive enhancer whose mode of action is considered to involve the release of free choline, which is then utilized for acetylcholine and phosphatidylcholine biosynthesis in the brain. The purpose of this study was to evaluate the profile of free plasma choline levels following a single i.m. dose of alpha-GPC in 12 normal volunteers. Citicoline (CTC), which also acts as a choline precursor, was included for comparison purposes. Each subject was studied on three randomized occasions, (i) in a control day in the absence of drug administration (to evaluate the plasma level profile of endogenous choline), (ii) after i.m. alpha-GPC (1,000 mg) and (iii) after i.m. CTC (1,000 mg) respectively, with a wash-out period of at least 1-week between sessions. Blood samples for plasma choline HPLC determinations were collected at regular intervals over a 6 h period. In the control session, plasma choline levels remained stable during the sampling period. The administration of alpha-GPC was associated with a rapid rise in plasma choline, peak levels being usually observed at the first (0.25 h) or second (0.5 h) sampling time after the injection. Thereafter, the concentration of choline declined gradually and returned to near baseline values at the end of the observation period. After the administration of CTC, plasma choline levels showed a similar time course but were considerably lower than those observed after the administration of alpha-GPC.(ABSTRACT TRUNCATED AT 250 WORDS) PMID: 1428296 [Indexed for MEDLINE]
4. J Int Med Res. 1991 Jul-Aug;19(4):330-41. doi: 10.1177/030006059101900406. A multicentre trial to evaluate the efficacy and tolerability of alpha-glycerylphosphorylcholine versus cytosine diphosphocholine in patients with vascular dementia. Di Perri R(1), Coppola G, Ambrosio LA, Grasso A, Puca FM, Rizzo M. Author information: (1)First Neurological Clinic, University of Messina, Italy. An open clinical trial was carried out to compare the efficacy and the tolerability of 1 g/day alpha-glycerylphosphorylcholine (alpha-GPC) with 1 g/day cytosine diphosphocholine (CDP) both given intramuscularly for 90 days in 120 patients with mild to moderate vascular dementia. The clinical evaluation, carried out at the start as well as halfway through (45 days) and at the end of treatment (90 days), was expressed by psychometric tests (modified Parkside behaviour rating scale, Sandoz clinical assessment geriatric scale, word fluency test, Hamilton's rating scale of depression, narration subtest of Wechsler memory scale). Both treatments produced a definite symptomatic improvement and showed a very good tolerability. The results suggest that in most tests alpha-GPC possessed a statistical higher efficacy and an overall more satisfactory activity assessed by both patients and investigators compared with CDP. DOI: 10.1177/030006059101900406 PMID: 1916007 [Indexed for MEDLINE]
⚠️ 면책 고지
이 정보는 일반 교육 목적이며 의료 진단/처방을 대체하지 않습니다.